Two Year Data from FAME 2 Trial Shows Sustained Benefits of FFR-Guided PCI over Medical Treatment in Patients with ...

St. Jude Medical, Inc. , a global medical device company, today announced primary outcome two-year data from the FAME 2 Trial which demonstrated sustained superiority with FFR-guided PCI using St.



from Content Keyword RSS http://ift.tt/1nuv98m

via IFTTT